Duke Cancer Institute (DCI) - Duke Cancer Center

Durham, North Carolina 27710-2000

0 studies enrolling now · 2 studies all time

What they study most

Advanced Solid Tumor, Advanced Urothelial Carcinoma, Bladder Cancer, Castration-resistant Prostate Cancer, Colorectal Cancer, FGFR3 Gene Alteration, FGFR3 Gene Mutation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Non-muscle-invasive Bladder Cancer, Non-small Cell Lung Cancer, Solid Tumor

Studies at this site

• Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations — Running, not enrolling
• A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors — Stopped early